Cargando…

Therapeutic effects of pegylated-interferon-α2a in a mouse model of multiple sclerosis

INTRODUCTION: Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS). EAE is mainly mediated by adaptive and innate immune responses that lead to an inflammatory demyelination and axonal damage. The aim of the present research was to examine the therapeutic eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Afraei, Sanaz, Sedaghat, Reza, Zavareh, Farzaneh Tofighi, Aghazadeh, Zahra, Ekhtiari, Parvin, Azizi, Gholamreza, Mirshafiey, Abbas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Polish Society of Experimental and Clinical Immunology 2018
Materias:	Experimental Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927168/ https://www.ncbi.nlm.nih.gov/pubmed/29731688 http://dx.doi.org/10.5114/ceji.2018.74868

Ejemplares similares

Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis
por: Afraei, Sanaz, et al.
Publicado: (2017)

Hydroxycitric acid ameliorates inflammation and oxidative stress in mouse models of multiple sclerosis
por: Goudarzvand, Mahdi, et al.
Publicado: (2016)

Evaluation of cell adhesion molecules (LFA-1 and L-selectin) in ankylosing spondylitis patients after treatment with β-D-mannuronic acid (M2000)
por: Fattahi, Mohammad Javad, et al.
Publicado: (2023)

Efficacy and Safety of G2013 as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells
por: ARJOMAND FARD, Nazanin, et al.
Publicado: (2017)

Effects of β-d-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, RORγt, IL4 and GATA3 gene expressions in rheumatoid arthritis patients
por: Barati, Anis, et al.
Publicado: (2017)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
por: Reuss, Reinhard
Publicado: (2013)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

The Role of Different Subsets of Regulatory T Cells in Immunopathogenesis of Rheumatoid Arthritis
por: Gol-Ara, Maryam, et al.
Publicado: (2012)

HLA antigens and anti-sperm antibody production in Iranian vasectomized men
por: Azizi, Gholamreza, et al.
Publicado: (2015)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

The Newly Identified T Helper 22 Cells Lodge in Leukemia
por: Azizi, Gholamreza, et al.
Publicado: (2015)

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2018)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C
por: Ding, Yan-Hua, et al.
Publicado: (2017)

Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
por: Groves, M D, et al.
Publicado: (2009)

Unusual Side Effects of Interferon Beta-1a in Patient with Multiple Sclerosis
por: Tavakoli, Maryam, et al.
Publicado: (2012)

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
por: Furber, Kendra L, et al.
Publicado: (2017)

A case of classic neuromyelitis optica (Devic’s syndrome) triggered by pegylated-interferon α
por: Mangioni, Davide, et al.
Publicado: (2014)

Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience
por: Bahcecioglu, Ibrahim Halil, et al.
Publicado: (2015)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy
por: Refaat, Bassem, et al.
Publicado: (2015)

Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
por: Turker, Kamuran, et al.
Publicado: (2015)

Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
por: Haagmans, Bart L, et al.
Publicado: (2004)

Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C
por: Daneshvar, Mahtab, et al.
Publicado: (2016)

Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C
por: Hu, Jing-Hong, et al.
Publicado: (2019)

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
por: Dolatimehr, Fardin, et al.
Publicado: (2017)

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
por: Huang, Yi-Wen, et al.
Publicado: (2022)

Early Treatment with Pegylated Interferon Lambda for Covid-19
por: Reis, Gilmar, et al.
Publicado: (2023)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Pegylated Interferon-α2a Inhibits Proliferation of Human Liver Cancer Cells In Vitro and In Vivo
por: Kusano, Hironori, et al.
Publicado: (2013)

Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α
por: Michelin, Márcia Antoniazi, et al.
Publicado: (2015)

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C
por: Rathi, Chetan, et al.
Publicado: (2015)

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B
por: Su, Qian, et al.
Publicado: (2018)

A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A
por: De Novellis, Danilo, et al.
Publicado: (2022)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

B cells and T cells abnormalities in patients with selective IgA deficiency
por: Bagheri, Yasser, et al.
Publicado: (2023)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9pla5cpdcpcsim4p6tspbult2h